Unresponsiveness to CHOP Is Associated with Activation of the p38 MAPK Pathway in Patients with DLBCL

Abstract▪2647▪This icon denotes a clinically relevant abstract We have reported in B-NHL cell lines that the p38 MAPK was constitutively activated and was involved in the regulation of tumor cell resistance to cytotoxic drugs. Further, inhibition of this pathway reversed drug resistance. Based in th...

Full description

Saved in:
Bibliographic Details
Published in:Blood 2011-11, Vol.118 (21), p.2647-2647
Main Authors: Vega, Mario I, Aviles-Salas, Alejandro, Chalapud, J Ramon, Huerta-Yepez, Sara, Hernandez-Pando, Rogelio, Martinez-Paniagua, Melisa, Martinez-Miguel, Bernardo, Hernandez-Atenogenes, Miriam, Vega, Gabriel G, Chen, Haiming, Berenson, James R., Mayani, Hector, Martinez-Maza, Otoniel, Bonavida, Benjamin
Format: Article
Language:English
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Abstract▪2647▪This icon denotes a clinically relevant abstract We have reported in B-NHL cell lines that the p38 MAPK was constitutively activated and was involved in the regulation of tumor cell resistance to cytotoxic drugs. Further, inhibition of this pathway reversed drug resistance. Based in these findings we hypothesized that the activation of the p38 MAPK pathway in patients with B-NHL may be associated with unresponsiveness to cytotoxic drug therapy. This study was designed to test this hypothesis. Eighty patients with Diffused Large B Cell Lymphoma (DLBCL) were used for analysis. Freshly derived tumor tissues from these patients were obtained from biopsies prior to any treatment. Tissue microarrays were prepared and examined by immunohistochemistry for the expression of both p38 MAPK and phosphorylated p38 MAPK (active). The antibodies were tested for specificity. The frequency of stained cells
ISSN:0006-4971
1528-0020
DOI:10.1182/blood.V118.21.2647.2647